NEW DELHI – Marking what may be a first, Mylan NV and Biocon Ltd. have submitted Mylan's biologics license application (BLA) to the FDA for a proposed biosimilar of branded trastuzumab, MYL-1401O, to treat certain forms of breast and gastric cancers.